CPT® Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

Most recent changes to the CPT® Category I New SARS-CoV-2 Vaccine Codes Long Descriptor document:

- Addition of 2 Category I codes (0173A, 91317) accepted by the CPT Editorial Panel. Codes 0173A, 91317, and all related references will be published in CPT 2024. Guidelines and parenthetical notes are only effective for codes that have received FDA Emergency Use Authorization (EUA) approval.
- Updated effective date for codes 0164A and 91316.
- Removal of FDA approval pending symbol () from code 91316.
- Updated code range to 91300-91317 by replacing 91316 with 91317 throughout the code set.

It is important to note that further CPT Editorial Panel or Executive Committee actions may affect these codes and/or descriptors. For this reason, code numbers and/or descriptor language in the CPT code set may differ at the time of publication. In addition, further Panel actions may result in gaps in code number sequencing.


<table>
<thead>
<tr>
<th>Codes</th>
<th>Long Descriptor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evaluation and Management Preventive Medicine Services</td>
<td></td>
</tr>
</tbody>
</table>

| Revised Guidelines Released to AMA Website |
| Revised Guidelines Effective |
| Publication |
| November 10, 2020 |
| December 17, 2020 |
| January 19, 2021 |
| March 1, 2021 |
| May 4, 2021 |
| July 30, 2021 |
| August 16, 2021 |
| New and Revised Guidelines Effective |
| 0001A, 0002A, 91300: December 11, 2020 |
| 0011A, 0012A, 91301: December 18, 2020 |
| 0031A, 91303: February 27, 2021 |
| 0003A, 0013A: August 12, 2021 |

CPT® 2022/2023/2024

CPT © Copyright 2022 American Medical Association. All rights reserved. AMA and CPT are registered trademarks of the American Medical Association. Updated December 9, 2022
<table>
<thead>
<tr>
<th>Date</th>
<th>Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>September 3, 2021</td>
<td>0004A: September 22, 2021</td>
</tr>
<tr>
<td>October 6, 2021</td>
<td>0034A, 0064A, 91306: October 20, 2021</td>
</tr>
<tr>
<td>October 27, 2021</td>
<td>0051A, 0052A, 0053A, 0054A, 0071A, 0072A,</td>
</tr>
<tr>
<td>January 12, 2022</td>
<td>91305, 91307: October 29, 2021</td>
</tr>
<tr>
<td>February 1, 2022</td>
<td>0073A: January 3, 2022</td>
</tr>
<tr>
<td>March 7, 2022</td>
<td>0094A, 91309: March 29, 2022</td>
</tr>
<tr>
<td>April 6, 2022</td>
<td>0074A: May 17, 2022</td>
</tr>
<tr>
<td>May 19, 2022</td>
<td>0081A, 0082A, 0083A, 0091A, 0092A, 0093A,</td>
</tr>
<tr>
<td>June 7, 2022</td>
<td>0111A, 0112A, 0113A, 91308, 91311: June 17, 2022</td>
</tr>
<tr>
<td>July 6, 2022</td>
<td>0041A, 0042A, 91304: July 13, 2022</td>
</tr>
<tr>
<td>August 31, 2022</td>
<td>0124A, 0134A (18 years and older): August 31, 2022</td>
</tr>
<tr>
<td>October 10, 2022</td>
<td>0134A (12 years through 17 years), 0144A, 0154A, 91315: October 12, 2022</td>
</tr>
<tr>
<td>November 16, 2022</td>
<td>0164A, 0173A, 91316, 91317: December 8, 2022</td>
</tr>
<tr>
<td>December 9, 2022</td>
<td>0021A, 0022A, 0044A, 0104A, 91302, 91310: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</td>
</tr>
</tbody>
</table>
**CPT® Category I New SARS-CoV-2 Vaccine Codes Long Descriptors**

| CPT © Copyright 2022 American Medical Association. All rights reserved. AMA and CPT are registered trademarks of the American Medical Association. Updated December 9, 2022 |

<table>
<thead>
<tr>
<th>Medicine Immunization Administration for Vaccines/Toxoids</th>
</tr>
</thead>
</table>

Report codes 90460 and 90461 only when the physician or other qualified health care professional provides face-to-face counseling of the patient/family during the administration of a vaccine other than when performed for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccines. For immunization administration of any vaccine, other than SARS-CoV-2 (coronavirus disease [COVID-19]) vaccines, that is not accompanied by face-to-face physician or other qualified health care professional counseling to the patient/family/guardian or for administration of vaccines to patients over 18 years of age, report 90471-90474. (See also Instructions for Use of the CPT Codebook for definition of reporting qualifications.)

▶ Report 0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0124A, 0134A, 0144A, 0154A, 0164A, 0173A for immunization administration of SARS-CoV-2 (coronavirus disease [COVID-19]) vaccines only. Each administration code is specific to each individual vaccine product (eg, 91300-91317, 91316, 91319, 91318, 91315, 91311, 91310, 91301, 91302, 91303, 91304, 91305, 91306, 91307, 91308, 91309), the dosage schedule (eg, first dose, second dose), and counseling, when performed. The appropriate administration code is chosen based on the type of vaccine and the specific dose number the patient receives in the schedule. For example, 0012A is reported for the second dose of vaccine 91301. Do not report 90460-90474 for the administration of SARS-CoV-2 (coronavirus disease [COVID-19]) vaccines. Codes related to SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine administration are listed in Appendix Q, with their associated vaccine code descriptors, vaccine administration codes, patient age, vaccine manufacturer, vaccine name(s), National Drug Code (NDC) Labeler Product ID, and interval between doses. In order to report these codes, the vaccine must fulfill the code descriptor and must be the vaccine represented by the manufacturer and vaccine name listed in Appendix Q. |

If a significant separately identifiable Evaluation and Management service (eg, new or established patient office or other outpatient services [99202-99215], office or other...

**New and Revised Guidelines Released to AMA Website**

<table>
<thead>
<tr>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>November 10, 2020</td>
</tr>
<tr>
<td>December 17, 2020</td>
</tr>
<tr>
<td>January 19, 2021</td>
</tr>
<tr>
<td>March 1, 2021</td>
</tr>
<tr>
<td>May 4, 2021</td>
</tr>
<tr>
<td>July 30, 2021</td>
</tr>
<tr>
<td>August 16, 2021</td>
</tr>
<tr>
<td>September 3, 2021</td>
</tr>
<tr>
<td>October 6, 2021</td>
</tr>
<tr>
<td>October 27, 2021</td>
</tr>
<tr>
<td>January 12, 2022</td>
</tr>
<tr>
<td>February 1, 2022</td>
</tr>
<tr>
<td>March 7, 2022</td>
</tr>
<tr>
<td>April 26, 2022</td>
</tr>
<tr>
<td>May 19, 2022</td>
</tr>
<tr>
<td>June 7, 2022</td>
</tr>
<tr>
<td>July 6, 2022</td>
</tr>
<tr>
<td>August 31, 2022</td>
</tr>
<tr>
<td>October 10, 2022</td>
</tr>
<tr>
<td>November 16, 2022</td>
</tr>
</tbody>
</table>

**New and Revised Guidelines Effective**

<table>
<thead>
<tr>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>December 11, 2020</td>
</tr>
<tr>
<td>December 18, 2020</td>
</tr>
<tr>
<td>February 27, 2021</td>
</tr>
<tr>
<td>August 12, 2021</td>
</tr>
<tr>
<td>September 22, 2021</td>
</tr>
<tr>
<td>October 20, 2021</td>
</tr>
<tr>
<td>October 29, 2021</td>
</tr>
<tr>
<td>January 3, 2022</td>
</tr>
<tr>
<td>March 29, 2022</td>
</tr>
<tr>
<td>May 17, 2022</td>
</tr>
<tr>
<td>July 13, 2022</td>
</tr>
</tbody>
</table>

**New and Revised Guidelines Publication**

CPT® 2022/2023/2024
<table>
<thead>
<tr>
<th>CPT® Category I New SARS-CoV-2 Vaccine Codes Long Descriptors</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>90460</strong> Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered</td>
</tr>
<tr>
<td><strong>90461</strong> each additional vaccine or toxoid component administered (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>(Use 90460 for each vaccine administered. For vaccines with multiple components [combination vaccines], report 90460 in conjunction with 90461 for each additional component in a given vaccine)</td>
</tr>
<tr>
<td>►(Do not report 90460, 90461 in conjunction with 91300-91301, 91303, 91304, 91305, 91306, 91307, 91308, 91309, unless both a severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease [COVID-19]] vaccine/toxoid product and at least one vaccine/toxoid product from 90476-90759 are administered at the same encounter)◄</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0134A</td>
<td>(12 years through 17 years), 0144A, 0154A, 91315: October 12, 2022</td>
</tr>
<tr>
<td>0164A, 0173A, 91316, 91317: December 8, 2022</td>
<td></td>
</tr>
<tr>
<td>0021A, 0022A, 0044A, 0104A, 91302, 91310: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</td>
<td></td>
</tr>
<tr>
<td>90460</td>
<td>Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered</td>
</tr>
<tr>
<td>90461</td>
<td>each additional vaccine or toxoid component administered (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>(Use 90460 for each vaccine administered. For vaccines with multiple components [combination vaccines], report 90460 in conjunction with 90461 for each additional component in a given vaccine)</td>
<td></td>
</tr>
<tr>
<td>►(Do not report 90460, 90461 in conjunction with 91300-91301, 91303, 91304, 91305, 91306, 91307, 91308, 91309, unless both a severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease [COVID-19]] vaccine/toxoid product and at least one vaccine/toxoid product from 90476-90759 are administered at the same encounter)◄</td>
<td></td>
</tr>
</tbody>
</table>

**New Parenthetical Note Released to AMA Website**
- November 10, 2020
- December 17, 2020
- January 19, 2021
- March 1, 2021
- May 4, 2021
- September 3, 2021
- October 6, 2021
- February 1, 2022
- March 7, 2022
- April 26, 2022

**New and Revised Parenthetical Note Effective**
- 91300: December 11, 2020
- 91301: December 18, 2020
- 91303: February 27, 2021
- 91306: October 20, 2021
- 91305, 91307: October 29, 2021
- 91309: March 29, 2022
- 91308, 91311: June 17, 2022
- 91304: July 13, 2022
- 91315: October 12, 2022

**New and Revised Parenthetical Note Publication CPT® 2022/2023/2024**
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>New SARS-CoV-2 Vaccine Codes Long Descriptors</th>
<th>New and Revised Parenthetical Note Effective</th>
</tr>
</thead>
</table>
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) (Do not report 90471 in conjunction with 90473) | May 19, 2022  
August 31, 2022  
November 16, 2022  
December 9, 2022 |  
91316, 91317: December 8, 2022  
91302, 91310: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration |
| 90472 | each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure) (Use 90472 in conjunction with 90460, 90471, 90473) | New and Revised Parenthetical Note Released to AMA Website  
November 10, 2020  
Revised Parenthetical Note Released to AMA Website  
December 17, 2020  
January 19, 2021  
March 1, 2021  
May 4, 2021  
September 3, 2021 |  
91300: December 11, 2020  
91301: December 18, 2020  
91303: February 27, 2021  
91306: October 20, 2021  
91305, 91307: October 29, 2021  
91309: March 29, 2022  
91308, 91311: June 17, 2022 |
<table>
<thead>
<tr>
<th>90473</th>
<th>Immunization administration by intranasal or oral route; 1 vaccine (single or combination vaccine/toxoid) (Do not report 90473 in conjunction with 90471)</th>
</tr>
</thead>
<tbody>
<tr>
<td>♦90474</td>
<td>each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure) (Do not report 90473, 90474 in conjunction with 91300-91317, 91304, 91305, 91306, 91307, 91308, 91309, unless both a severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine/toxoid product and at least one vaccine/toxoid product from 90476-90759 are administered at the same encounter)</td>
</tr>
</tbody>
</table>

| October 6, 2021 | 91304: July 13, 2022 |
| February 1, 2022 | 91315: October 12, 2022 |
| March 7, 2022 | 91316, 91317: December 8, 2022 |
| April 26, 2022 | 91302, 91310: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration |
| May 19, 2022 | |
| August 31, 2022 | |
| November 16, 2022 | |
| December 9, 2022 | |

**New Parenthetical Note Released to AMA Website**
- November 10, 2020
- December 17, 2020
- January 19, 2021
- March 1, 2021
- May 4, 2021
- September 3, 2021
- October 6, 2021
- February 1, 2022
- March 7, 2022
- April 26, 2022
- May 19, 2022
- August 31, 2022
- November 16, 2022

**New and Revised Parenthetical Note Effective**
- 91300: December 11, 2020
- 91301: December 18, 2020
- 91303: February 27, 2021
- 91306: October 20, 2021
- 91305, 91307: October 29, 2021
- 91309: March 29, 2022
- 91308, 91311: June 17, 2022
- 91304: July 13, 2022
- 91315: October 12, 2022
- 91316, 91317: December 8, 2022
- 91302, 91310: Effective upon receiving

**New and Revised Parenthetical Note Publication CPT® 2022/2023/2024**
# CPT® Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Date Range</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0001A</td>
<td>Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; first dose</td>
<td>November 10, 2020 - December 11, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>0002A</td>
<td>Second dose</td>
<td>November 10, 2020 - December 11, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>0003A</td>
<td>Third dose</td>
<td>July 30, 2021 - August 12, 2021</td>
<td>CPT® 2023</td>
</tr>
<tr>
<td>0004A</td>
<td>Booster dose</td>
<td>September 3, 2021 - October 9, 2022</td>
<td>CPT® 2022/2023/2024</td>
</tr>
<tr>
<td>#0051A</td>
<td>Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose</td>
<td>September 3, 2021 - October 29, 2021</td>
<td>CPT® 2023</td>
</tr>
<tr>
<td>#0052A</td>
<td>Second dose</td>
<td>September 3, 2021 - October 29, 2021</td>
<td>CPT® 2023</td>
</tr>
<tr>
<td>#0053A</td>
<td>Third dose</td>
<td>September 3, 2021 - October 29, 2021</td>
<td>CPT® 2023</td>
</tr>
<tr>
<td>#0054A</td>
<td>Booster dose</td>
<td>September 3, 2021 - September 8, 2022</td>
<td>CPT® 2023/2024</td>
</tr>
</tbody>
</table>
## CPT® Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Date</th>
<th>Start</th>
<th>End</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>0051A</td>
<td>Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, booster dose</td>
<td>February 1, 2022</td>
<td>0051A, 0052A, 0053A, 0054A for the administration of vaccine 91305</td>
<td>August 31, 2022</td>
<td>(Report 0051A, 0052A, 0053A, 0054A in conjunction with 91300, 91307, 91312, 91315, 91317) (Do not report 0051A, 0052A, 0053A, 0054A in conjunction with 91300, 91307, 91312, 91315, 91317)</td>
</tr>
<tr>
<td>0071A</td>
<td>Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose</td>
<td>October 6, 2021</td>
<td>0071A, 0072A, 0073A, 0074A for the administration of vaccine 91307</td>
<td>October 29, 2021</td>
<td>(Report 0071A, 0072A, 0073A, 0074A for the administration of vaccine 91307) (Do not report 0071A, 0072A, 0073A, 0074A in conjunction with 91300, 91305, 91307, 91312, 91315, 91317)</td>
</tr>
<tr>
<td>0072A</td>
<td>second dose</td>
<td>October 6, 2021</td>
<td>0071A, 0072A, 0073A, 0074A for the administration of vaccine 91307</td>
<td>October 29, 2021</td>
<td></td>
</tr>
<tr>
<td>0073A</td>
<td>third dose</td>
<td>January 12, 2022</td>
<td>0071A, 0072A, 0073A, 0074A for the administration of vaccine 91307</td>
<td>January 3, 2022</td>
<td></td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td>Date</td>
<td>Codes</td>
<td>Notes</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>------------------------------------------------------------------------------</td>
<td>-------------------</td>
<td>--------------------------------------------</td>
<td>------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>#0154A</td>
<td>Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose</td>
<td>August 31, 2022</td>
<td>0074A: May 17, 2022; 91308: June 17, 2022; 91312: August 31, 2022; 91315: October 12, 2022; 91317: December 8, 2022</td>
<td>CPT® 2024 (Do not report 0154A in conjunction with 91300, 91305, 91307, 91308, 91312, 91315, 91317)</td>
<td></td>
</tr>
<tr>
<td>#0081A</td>
<td>Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose</td>
<td>February 1, 2022</td>
<td>91300: December 11, 2020; 91305, 91307: October 29, 2021; 91308: June 17, 2022; 91312: August 31, 2022; 0154A, 91315: October 12, 2022; 91317: December 8, 2022</td>
<td>CPT® 2023</td>
<td></td>
</tr>
<tr>
<td>#0082A</td>
<td>second dose</td>
<td>February 1, 2022</td>
<td>91300: December 11, 2020; 91305, 91307: October 29, 2021; 91308: June 17, 2022; 91312: August 31, 2022; 0154A, 91315: October 12, 2022; 91317: December 8, 2022</td>
<td>CPT® 2023</td>
<td></td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td>Date</td>
<td>Date</td>
<td>Code</td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------------</td>
<td>-----------------------------</td>
<td>-------------------------------------------</td>
<td></td>
</tr>
</tbody>
</table>
| #0173A    | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose  
  ► (Report 0173A for the administration of vaccine 91317)  
  ► (Use 0173A in conjunction with 91317 only when used as a third dose administration of primary series for 91308, [ie, following administration of 0081A, 0082A])  
  ► (Do not report 0173A in conjunction with 91300, 91305, 91307, 91308, 91312, 91315) | December 9, 2022   | 91300: December 11, 2020   | 91317: December 8, 2022               |
| 0011A     | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; first dose | November 10, 2020   | December 18, 2020           | CPT® 2022                                |
| 0012A     | second dose                                                                                                                                                                                                  | November 10, 2020   | December 18, 2020           | CPT® 2022                                |
| 0013A     | third dose  
  ► (Report 0011A, 0012A, 0013A for the administration of vaccine 91301)  

New Parenthetical Note Released to AMA Website
March 7, 2022

Revised Parenthetical Note Released to AMA Website
May 19, 2022
August 31, 2022
November 16, 2022

91306: October 20, 2021
91309: March 29, 2022
91311: June 17, 2022
91313 (18 years and older): August 31, 2022
91313 (12 years through 17 years),
<table>
<thead>
<tr>
<th>CPT® Category I New SARS-CoV-2 Vaccine Codes Long Descriptors</th>
</tr>
</thead>
<tbody>
<tr>
<td>91314: October 12, 2022</td>
</tr>
<tr>
<td>91316: December 8, 2022</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>#●0064A</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>September 3, 2021</td>
</tr>
<tr>
<td>March 7, 2022</td>
</tr>
<tr>
<td>May 19, 2022</td>
</tr>
<tr>
<td>November 16, 2022</td>
</tr>
<tr>
<td>91301: December 18, 2020</td>
</tr>
<tr>
<td>0064A, 91306: October 20, 2021</td>
</tr>
<tr>
<td>91309: March 29, 2022</td>
</tr>
<tr>
<td>91311: June 17, 2022</td>
</tr>
<tr>
<td>91313 (18 years and older): August 31, 2022</td>
</tr>
<tr>
<td>91313 (12 years through 17 years), 91314: October 12, 2022</td>
</tr>
<tr>
<td>91316: December 8, 2022</td>
</tr>
<tr>
<td>CPT® 2023/2024</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>#●0134A</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>August 31, 2022</td>
</tr>
<tr>
<td>November 16, 2022</td>
</tr>
<tr>
<td>91301: December 18, 2020</td>
</tr>
<tr>
<td>91306: October 20, 2021</td>
</tr>
<tr>
<td>91309: March 29, 2022</td>
</tr>
<tr>
<td>91311: June 17, 2022</td>
</tr>
<tr>
<td>0134A and 91313 (18 years and older): August 31, 2022</td>
</tr>
<tr>
<td>0134A and 91313 (12 years through 17 years), 91314: October 12, 2022</td>
</tr>
<tr>
<td>91316: December 8, 2022</td>
</tr>
<tr>
<td>CPT® 2024</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>#●0144A</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>August 31, 2022</td>
</tr>
<tr>
<td>November 16, 2022</td>
</tr>
<tr>
<td>91301: December 18, 2020</td>
</tr>
<tr>
<td>CPT® 2024</td>
</tr>
<tr>
<td>Code</td>
</tr>
<tr>
<td>--------</td>
</tr>
<tr>
<td>#●0091A</td>
</tr>
<tr>
<td>#●0092A</td>
</tr>
<tr>
<td>#●0093A</td>
</tr>
<tr>
<td>#▲●0094A</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

CPT © Copyright 2022 American Medical Association.
All rights reserved. AMA and CPT are registered trademarks of the American Medical Association.
Updated December 9, 2022
<table>
<thead>
<tr>
<th>CPT Code</th>
<th>Description</th>
<th>Date Code Released</th>
<th>Date Code Effective</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>0021A</td>
<td>Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10^10 viral particles/0.5 mL dosage; first dose</td>
<td>December 17, 2020</td>
<td>Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>0022A</td>
<td>second dose</td>
<td>December 17, 2020</td>
<td>Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>0031A</td>
<td>Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10^10 viral particles/0.5 mL dosage; single dose</td>
<td>January 19, 2021</td>
<td>Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</td>
<td>CPT® 2022/2023</td>
</tr>
<tr>
<td>0034A</td>
<td>booster dose</td>
<td>October 27, 2021</td>
<td>Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</td>
<td>CPT® 2023</td>
</tr>
<tr>
<td>0041A</td>
<td>Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage; first dose</td>
<td>May 4, 2021</td>
<td>July 13, 2022</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>0042A</td>
<td>second dose</td>
<td>May 4, 2021</td>
<td>July 13, 2022</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>0044A</td>
<td>booster dose</td>
<td>October 10, 2022</td>
<td>Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</td>
<td>CPT® 2024</td>
</tr>
<tr>
<td>0104A</td>
<td>Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine,</td>
<td>April 26, 2022</td>
<td>Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</td>
<td>CPT® 2023</td>
</tr>
<tr>
<td>CPT® Category I New SARS-CoV-2 Vaccine Codes Long Descriptors</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>0111A</strong> Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>► (Report 0104A for the administration of vaccine 91310) ◄</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Authorization or approval from the Food and Drug Administration</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>May 19, 2022</td>
<td>June 17, 2022</td>
<td>CPT® 2023</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>0112A</strong> second dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>May 19, 2022</td>
<td>June 17, 2022</td>
<td>CPT® 2023</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>0113A</strong> third dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>► (Report 0111A, 0112A, 0113A for the administration of vaccine 91311) ◄</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>► (Do not report 0111A, 0112A, 0113A in conjunction with 91301, 91306, 91309, 91313, 91314, 91316) ◄</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>July 6, 2022</td>
<td>September 30, 2022</td>
<td>November 16, 2022</td>
<td></td>
<td></td>
</tr>
<tr>
<td>91301: December 18, 2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>91306: October 20, 2021</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>91309: March 29, 2022</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0111A, 0112A, 0113A, 91311: June 17, 2022</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>91313 (18 years and older): August 31, 2022</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>91313 (12 years through 17 years), 91314: October 12, 2022</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>91316: December 8, 2022</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>#0164A</strong> Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, booster dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>► (Report 0164A for the administration of vaccine 91316) ◄</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>► (Do not report 0164A in conjunction with 91301, 91306, 91309, 91311, 91313, 91314) ◄</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>November 16, 2022</td>
<td>91301: December 18, 2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>91306: October 20, 2021</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>91309: March 29, 2022</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>91311: June 17, 2022</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>91313 (18 years and older): August 31, 2022</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>91313 (12 years through 17 years), 91314: October 12, 2022</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>91316: December 8, 2022</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CPT® 2024</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Vaccines, Toxoids

To assist users to report the most recent new or revised vaccine product codes, the American Medical Association (AMA) currently uses the CPT website, which features updates of CPT Editorial Panel actions regarding these products. Once approved by the CPT Editorial Panel, these codes will be made available for release on a semiannual (twice a year: July 1 and January 1) basis. As part of the electronic distribution, there is a six-month implementation period from the initial release date (ie, codes released on January 1 are eligible for use on July 1 and codes released on July 1 are eligible for use January 1).

The CPT Editorial Panel, in recognition of the public health interest in vaccine products, has chosen to publish new vaccine product codes prior to approval by the US Food and Drug Administration (FDA). These codes are indicated with the symbol and will be tracked by the AMA to monitor FDA approval status. Once the FDA status changes to approval, the symbol will be removed. CPT users should refer to the AMA CPT website (www.ama-assn.org/go/cpt-vaccine) for the most up-to-date information on codes with the symbol.

► Codes 90476-90759, 91300-91317, 91308, 91309 identify the vaccine product only. To report the administration of a vaccine/toxoid other than SARS-CoV-2 (coronavirus disease [COVID-19]), the vaccine/toxoid product codes (90476-90759) must be used in addition to an immunization administration code(s) (90460, 90461, 90471, 90472, 90473, 90474). To report the administration of a SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine, the vaccine/toxoid product codes (91300-91306, 91307, 91308, 91309) should be reported with the corresponding immunization administration codes.

<table>
<thead>
<tr>
<th>New and Revised Guidelines</th>
<th>New and Revised Guidelines</th>
<th>New and Revised Guidelines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Released to AMA Website</td>
<td>Effective</td>
<td>Publication</td>
</tr>
<tr>
<td>December 17, 2020</td>
<td>0011A, 0012A, 91301:</td>
<td></td>
</tr>
<tr>
<td>January 19, 2021</td>
<td>0031A, 91303:</td>
<td></td>
</tr>
<tr>
<td>March 1, 2021</td>
<td>0003A, 0013A:</td>
<td></td>
</tr>
<tr>
<td>May 4, 2021</td>
<td>0004A: September 22, 2021</td>
<td></td>
</tr>
<tr>
<td>July 30, 2021</td>
<td>0034A, 0064A, 91306:</td>
<td></td>
</tr>
<tr>
<td>August 16, 2021</td>
<td>91308: October 20, 2021</td>
<td></td>
</tr>
<tr>
<td>September 3, 2021</td>
<td></td>
<td></td>
</tr>
<tr>
<td>October 6, 2021</td>
<td></td>
<td></td>
</tr>
<tr>
<td>October 27, 2021</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**CPT® Category I New SARS-CoV-2 Vaccine Codes Long Descriptors**

<table>
<thead>
<tr>
<th>Date</th>
<th>Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>February 1, 2022</td>
<td>0073A: January 3, 2022</td>
</tr>
<tr>
<td>March 7, 2022</td>
<td>0094A, 91309: March 29, 2022</td>
</tr>
<tr>
<td>April 26, 2022</td>
<td>0074A; May 17, 2022</td>
</tr>
<tr>
<td>June 7, 2022</td>
<td>0041A, 0042A, 91304: July 13, 2022</td>
</tr>
<tr>
<td>July 6, 2022</td>
<td>0124A, 0134A (18 years and older): August 31, 2022</td>
</tr>
<tr>
<td>August 31, 2022</td>
<td>0134A (12 years through 17 years), 0144A, 0154A, 91315: October 12, 2022</td>
</tr>
<tr>
<td>October 10, 2022</td>
<td>0164A, 0173A, 91316, 91317: December 8, 2022</td>
</tr>
<tr>
<td>November 16, 2022</td>
<td>0021A, 0022A, 0044A, 0104A, 91302, 91310: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</td>
</tr>
<tr>
<td>December 9, 2022</td>
<td></td>
</tr>
</tbody>
</table>

The “when administered to” age descriptions included in CPT vaccine codes are not intended to identify a product’s licensed age indication. The term “preservative free” includes use for vaccines that contain no preservative and vaccines that contain trace amounts of preservative agents that are not present in a sufficient concentration for the purpose of preserving the final vaccine formulation. The absence of a designation regarding a preservative does not

---

The "when administered to" age descriptions included in CPT vaccine codes are not intended to identify a product's licensed age indication. The term “preservative free” includes use for vaccines that contain no preservative and vaccines that contain trace amounts of preservative agents that are not present in a sufficient concentration for the purpose of preserving the final vaccine formulation. The absence of a designation regarding a preservative does not...
necessarily indicate the presence or absence of preservative in the vaccine. Refer to the product’s prescribing information (PI) for the licensed age indication before administering vaccine to a patient.

Separate codes are available for combination vaccines (eg, Hib-HepB, DTap-IPV/Hib). It is inappropriate to code each component of a combination vaccine separately. If a specific vaccine code is not available, the unlisted procedure code should be reported, until a new code becomes available.

► The vaccine/toxoid abbreviations listed in codes 90476-90759, 91300-9131791316913159131391310, 91301, 91302, 91303, 91304, 91305, 91306, 91307, 91308, 91309 reflect the most recent US vaccine abbreviation references used in the Advisory Committee on Immunization Practices (ACIP) recommendations at the time of CPT code set publication. Interim updates to vaccine code descriptors will be made following abbreviation approval by the ACIP on a timely basis via the AMA CPT website (ama-assn.org/cpt-cat-i-vaccine-codes). The accuracy of the ACIP vaccine abbreviation designations in the CPT code set does not affect the validity of the vaccine code and its reporting function.

For the purposes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccinations, codes 0003A, 0013A, 0053A, 0073A, and 0083A, 0093A, and 0113A, and 0173A represent the administration of a third dose in the primary series (eg, patient with immunocompromising condition or patient age 6 months through 4 years) when the initial immune response following a two-dose primary vaccine series is likely to be insufficient (eg, immunocompromised patient). In contrast, the booster dose codes 0004A, 0034A, 0064A, 0074A, and 0084A, 0104A, 0124A, 0144A, and 0154A, and 0164A represent the administration of a dose of vaccine when the initial immune response to a primary vaccine series was sufficient, but has likely waned over time.

(For immune globulins, see 90281-90399. For administration of immune globulins, see 96365-96375)

<table>
<thead>
<tr>
<th>Date</th>
<th>Code(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>December 17, 2020</td>
<td>91301: December 18, 2020</td>
</tr>
<tr>
<td>January 19, 2021</td>
<td>91303: February 27, 2021</td>
</tr>
<tr>
<td>March 1, 2021</td>
<td>0003A, 0013A; August 12, 2021</td>
</tr>
<tr>
<td>May 4, 2021</td>
<td>0004A: September 22, 2021</td>
</tr>
<tr>
<td>September 3, 2021</td>
<td>0034A, 0064A, 91306: October 20, 2021</td>
</tr>
<tr>
<td>October 6, 2021</td>
<td>0053A, 0054A, 91305, 91307: October 29, 2021</td>
</tr>
<tr>
<td>October 27, 2021</td>
<td>0073A: January 3, 2022</td>
</tr>
<tr>
<td>January 12, 2022</td>
<td>0094A, 91309: March 29, 2022</td>
</tr>
<tr>
<td>February 1, 2022</td>
<td>0003A, 0013A, 0053A, 0073A, and 0083A, 0093A, and 0113A, and 0173A represent the administration of a third dose in the primary series (eg, patient with immunocompromising condition or patient age 6 months through 4 years) when the initial immune response following a two-dose primary vaccine series is likely to be insufficient (eg, immunocompromised patient). In contrast, the booster dose codes 0004A, 0034A, 0064A, 0074A, and 0084A, 0104A, 0124A, 0144A, and 0154A, and 0164A represent the administration of a dose of vaccine when the initial immune response to a primary vaccine series was sufficient, but has likely waned over time. (For immune globulins, see 90281-90399. For administration of immune globulins, see 96365-96375)</td>
</tr>
<tr>
<td>#91300</td>
<td>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use</td>
</tr>
<tr>
<td></td>
<td>(Report 91300 with administration codes 0001A, 0002A, 0003A, 0004A)</td>
</tr>
</tbody>
</table>

| #91305 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use |
| | (Report 91305 with administration codes 0051A, 0052A, 0053A, 0054A) |
| | (Do not report 91305 in conjunction with administration codes 0001A, 0002A, 0003A, 0004A, 0071A, 0072A, 0081A, 0082A, 0083A, 0124A, 0154A, 0173A) |
| September 3, 2021 | October 6, 2021 | January 12, 2022 | February 1, 2022 | April 26, 2022 | June 7, 2022 | August 31, 2022 | December 9, 2022 |

CPT® Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

CPT © Copyright 2022 American Medical Association. All rights reserved. AMA and CPT are registered trademarks of the American Medical Association. Updated December 9, 2022
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Date</th>
<th>Codes</th>
<th>Code</th>
<th>Description</th>
<th>Date</th>
<th>Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use</td>
<td></td>
<td>004A: September 22, 2021</td>
<td></td>
<td>10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation,</td>
<td>February 1, 2022</td>
<td>004A: September 22, 2021</td>
</tr>
<tr>
<td></td>
<td>▶ (Report 91312 with administration code 0124A)</td>
<td></td>
<td>0051A, 0052A, 0053A, 0071A, 0072A,</td>
<td></td>
<td>for intramuscular use</td>
<td>April 26, 2022</td>
<td>0051A, 0052A, 0053A, 0071A,</td>
</tr>
<tr>
<td></td>
<td>▶ (Do not report 91312 in conjunction with administration codes 0001A, 0002A,</td>
<td></td>
<td>0073A, 0074A, 0081A, 0082A, 0083A,</td>
<td></td>
<td>0072A: August 31, 2022</td>
<td>June 7, 2022</td>
<td>0072A: August 31, 2022</td>
</tr>
<tr>
<td></td>
<td>▶ (Report 91307 with administration codes 0071A, 0072A, 0073A, 0074A)</td>
<td></td>
<td></td>
<td></td>
<td>▶ (Report 91307 with administration codes 0071A, 0072A, 0073A, 0074A)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CPT® Copyright 2022 American Medical Association.
All rights reserved. AMA and CPT are registered trademarks of the American Medical Association.
Updated December 9, 2022
<table>
<thead>
<tr>
<th>Code</th>
<th>Date of Change</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>91315</td>
<td>August 31, 2022</td>
<td>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use</td>
</tr>
<tr>
<td></td>
<td></td>
<td>► (Report 91315 with administration code 0154A)◄</td>
</tr>
<tr>
<td>Category I New SARS-CoV-2 Vaccine Codes Long Descriptors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>► (Report 91308 with administration codes 0081A, 0082A, 0083A)◄</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>August 31, 2022</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>December 9, 2022</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>● 91317 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use</td>
<td></td>
<td></td>
</tr>
<tr>
<td>► (Report 91317 with administration code 0173A)◄</td>
<td></td>
<td></td>
</tr>
<tr>
<td>► (Use 91317 only as the third dose in the primary series, with the first two doses reported using 91308, 0081A, 0082A)◄</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>December 9, 2022</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CPT® 2024</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0001A, 0002A: December 11, 2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0003A: August 12, 2021</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0004A: September 22, 2021</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0073A: January 3, 2022</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0074A: May 17, 2022</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0081A, 0082A, 0083A: June 17, 2022</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0124A: August 31, 2022</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0154A: October 12, 2022</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0173A, 91317: December 8, 2022</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### #91301
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use

► (Report 91301 with administration codes 0011A, 0012A, 0013A)◄
► (Do not report 91301 in conjunction with administration codes 0064A, 0091A, 0092A, 0093A, 0094A, 0111A, 0112A, 0113A, 0134A, 0144A, 0164A)◄

<table>
<thead>
<tr>
<th>Date</th>
<th>Code(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>August 16, 2021</td>
<td>0013A: August 12, 2021</td>
</tr>
<tr>
<td></td>
<td>0064A: October 20, 2021</td>
</tr>
<tr>
<td></td>
<td>0094A: March 29, 2022</td>
</tr>
<tr>
<td></td>
<td>0091A, 0092A, 0093A, 0111A, 0112A, 0113A: June 17, 2022</td>
</tr>
<tr>
<td></td>
<td>0134A (18 years and older): August 31, 2022</td>
</tr>
<tr>
<td></td>
<td>0134A (12 years through 17 years), 0144A: October 12, 2022</td>
</tr>
<tr>
<td></td>
<td>0164A: December 8, 2022</td>
</tr>
</tbody>
</table>

### #91306
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use

► (Report 91306 with administration code 0064A)◄
► (Do not report 91306 in conjunction with administration codes 0011A, 0012A, 0013A, 0091A, 0092A, 0093A, 0094A, 0111A, 0112A, 0113A, 0134A, 0144A, 0164A)◄

<table>
<thead>
<tr>
<th>Date</th>
<th>Code(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>September 3, 2021</td>
<td>0011A, 0012A: December 18, 2020</td>
</tr>
<tr>
<td></td>
<td>0013A: August 12, 2021</td>
</tr>
<tr>
<td></td>
<td>0064A, 91306: October 20, 2021</td>
</tr>
<tr>
<td></td>
<td>0094A: March 29, 2022</td>
</tr>
<tr>
<td></td>
<td>0091A, 0092A, 0093A, 0111A, 0112A, 0113A: June 17, 2022</td>
</tr>
<tr>
<td></td>
<td>0134A (18 years and older): August 31, 2022</td>
</tr>
<tr>
<td></td>
<td>0134A (12 years through 17 years), 0144A: October 12, 2022</td>
</tr>
<tr>
<td></td>
<td>0164A: December 8, 2022</td>
</tr>
<tr>
<td>Category</td>
<td>Description</td>
</tr>
<tr>
<td>----------</td>
<td>-------------</td>
</tr>
<tr>
<td>#91313</td>
<td>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| #91314  | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use | 0164A: December 8, 2022 | August 31, 2022 to November 16, 2022 | CPT® 2024 |
|         |             |       |            | ►(Report 91314 with administration code 0144A)◄ |

CPT® 2024
| #91311 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use  
► (Report 91311 with administration codes 0111A, 0112A, 0113A)  
June 7, 2022  
August 31, 2022  
November 16, 2022 | 0064A: October 20, 2021  
0094A: March 29, 2022  
0091A, 0092A, 0093A, 0111A, 0112A, 0113A, 91311: June 17, 2022  
0134A (18 years and older): August 31, 2022  
0134A (12 years through 17 years), 0144A: October 12, 2022  
0164A: December 8, 2022 | CPT® 2023/2024 |
| #91316 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use  
► (Report 91316 with administration code 0164A)  
0013A: August 12, 2021  
0064A: October 20, 2021  
0094A: March 29, 2022  
0091A, 0092A, 0093A, 0111A, 0112A, 0113A, 91311: June 17, 2022  
0134A (18 years and older): August 31, 2022  
0134A (12 years through 17 years), 0144A: October 12, 2022  
0164A, 91316: December 8, 2022 | CPT® 2024 |
### CPT® Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Start Date</th>
<th>End Date</th>
<th>Codes Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>91309</td>
<td>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>► (Do not report 91309 in conjunction with administration codes 0011A, 0012A, 0013A, 0064A, 0111A, 0112A, 0113A, 0134A, 0144A, 0164A)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| 91302  | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10¹⁰ viral particles/0.5 mL dosage, for intramuscular use |
|        | ► (Report 91302 with administration codes 0021A, 0022A)                                                                                     | December 17, 2020 | Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration |

| 91303  | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10¹⁰ viral particles/0.5 mL dosage, for intramuscular use |
|        | ► (Report 91303 with administration codes 0031A, 0034A)                                                                                     | January 19, 2021  | October 27, 2021       | CPT® 2022/2023                                                                  |

<p>| 91304  | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use |
|        | ► (Report 91304 with administration codes 0041A, 0042A, 0044A)                                                                                | May 4, 2021      | October 10, 2022       | CPT® 2022/2023                                                                  |</p>
<table>
<thead>
<tr>
<th>CPT® Category I New SARS-CoV-2 Vaccine Codes Long Descriptors</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>#91310</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>April 26, 2022</strong></td>
</tr>
<tr>
<td><strong>90476</strong></td>
</tr>
<tr>
<td><strong>96372</strong></td>
</tr>
<tr>
<td>Therapeutic, Prophylactic, and Diagnostic Injections and Infusions (Excludes Chemotherapy and Other Highly Complex Drug or Highly Complex Biologic Agent Administration)</td>
</tr>
<tr>
<td>Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular</td>
</tr>
<tr>
<td><strong>Revised Parenthetical Note Released to AMA Website</strong></td>
</tr>
<tr>
<td>November 10, 2020</td>
</tr>
<tr>
<td>December 17, 2020</td>
</tr>
<tr>
<td>January 19, 2021</td>
</tr>
<tr>
<td>May 4, 2021</td>
</tr>
<tr>
<td>July 30, 2021</td>
</tr>
<tr>
<td>August 16, 2021</td>
</tr>
<tr>
<td>September 3, 2021</td>
</tr>
<tr>
<td>October 6, 2021</td>
</tr>
<tr>
<td>October 27, 2021</td>
</tr>
<tr>
<td>January 12, 2022</td>
</tr>
<tr>
<td>February 1, 2022</td>
</tr>
<tr>
<td>March 7, 2022</td>
</tr>
<tr>
<td>April 26, 2022</td>
</tr>
<tr>
<td>May 19, 2022</td>
</tr>
<tr>
<td>June 7, 2022</td>
</tr>
<tr>
<td>July 6, 2022</td>
</tr>
<tr>
<td>August 31, 2022</td>
</tr>
<tr>
<td>October 10, 2022</td>
</tr>
<tr>
<td>November 16, 2022</td>
</tr>
<tr>
<td>December 9, 2022</td>
</tr>
<tr>
<td><strong>Revised Parenthetical Note Effective</strong></td>
</tr>
<tr>
<td>0001A, 0002A: December 11, 2020</td>
</tr>
<tr>
<td>0011A, 0012A: December 18, 2020</td>
</tr>
<tr>
<td>0031A: February 27, 2021</td>
</tr>
<tr>
<td>0003A, 0013A: August 12, 2021</td>
</tr>
<tr>
<td>0004A: September 22, 2021</td>
</tr>
<tr>
<td>0034A, 0064A: October 20, 2021</td>
</tr>
<tr>
<td>0073A: January 3, 2022</td>
</tr>
<tr>
<td>0094A: March 29, 2022</td>
</tr>
<tr>
<td>0074A: May 17, 2022</td>
</tr>
<tr>
<td>0041A, 0042A: July 13, 2022</td>
</tr>
</tbody>
</table>

---

CPT® Copyright 2022 American Medical Association.
All rights reserved. AMA and CPT are registered trademarks of the American Medical Association.
Updated December 9, 2022
### Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Vaccines


### New Appendix Q Released to AMA Website
- November 10, 2020
- Revised Appendix Q Released to AMA Website
- December 17, 2020
- January 19, 2021
- May 4, 2021
- July 30, 2021
- August 16, 2021
- September 3, 2021
- October 6, 2021
- October 27, 2021
- January 12, 2022
- February 1, 2022
- March 7, 2022
- April 26, 2022

### Appendix Q Effective
- 0001A, 0002A, 91300: December 11, 2020
- 0011A, 0012A, 91301: December 18, 2020
- 0031A, 91303: February 27, 2021
- 0003A, 0013A: August 12, 2021
- 0004A: September 22, 2021
- 0034A, 0064A, 91306: October 20, 2021
- 0051A, 0052A, 0053A, 0054A: October 29, 2021
- 0071A, 0072A, 0073A: January 3, 2022
<table>
<thead>
<tr>
<th>Date</th>
<th>Codes Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>May 19, 2022</td>
<td>0094A, 91309: March 29, 2022</td>
</tr>
<tr>
<td>June 7, 2022</td>
<td>0074A: May 17, 2022</td>
</tr>
<tr>
<td>August 31, 2022</td>
<td>0041A, 0042A, 91304: July 13, 2022</td>
</tr>
<tr>
<td>October 10, 2022</td>
<td>0124A, 0134A (18 years and older): August 31, 2022</td>
</tr>
<tr>
<td>November 16, 2022</td>
<td>0134A (12 years through 17 years), 0144A, 0154A, 91315: October 12, 2022</td>
</tr>
<tr>
<td>December 9, 2022</td>
<td>0164A, 0173A, 91316, 91317: December 8, 2022</td>
</tr>
<tr>
<td></td>
<td>0021A, 0022A, 0044A, 0104A, 91302, 91310: Effective upon receiving</td>
</tr>
<tr>
<td></td>
<td>Emergency Use Authorization or approval from the Food and Drug Administration</td>
</tr>
<tr>
<td>Vaccine Code</td>
<td>Vaccine Administration Code(s)</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------</td>
</tr>
<tr>
<td>#●91300</td>
<td>●0001A (1st Dose) ●0002A (2nd Dose) ●0003A (3rd Dose) ●0004A (Booster)</td>
</tr>
<tr>
<td>#●91305</td>
<td>●0051A (1st Dose) ●0052A (2nd Dose) ●0053A (3rd Dose) ●0054A (Booster)</td>
</tr>
<tr>
<td>#●91312</td>
<td>●0124A (Booster)</td>
</tr>
</tbody>
</table>
### CPT® Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

<table>
<thead>
<tr>
<th>Vaccine Code</th>
<th>Vaccine Administration Code(s)</th>
<th>Patient Age</th>
<th>Vaccine Manufacturer</th>
<th>Vaccine Name(s)</th>
<th>NDC 10/NDC 11 Labeler Product ID (Vial)</th>
<th>Dosing Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>#91307</td>
<td>#0071A (1st Dose) #0072A (2nd Dose) #0073A (3rd Dose) #0074A (Booster)</td>
<td>5 years through 11 years</td>
<td>Pfizer, Inc</td>
<td>Pfizer-BioNTech COVID-19 Vaccine</td>
<td>59267-1055-1 59267-1055-01</td>
<td>1st Dose to 2nd Dose: 21 Days 2nd Dose to 3rd Dose (CDC recommended population[s] [eg, immunocompromised]) 28 or More Days Booster: Refer to FDA/CDC Guidance</td>
</tr>
<tr>
<td>#91315</td>
<td>#0154A (Booster)</td>
<td>5 years through 11 years</td>
<td>Pfizer, Inc</td>
<td>Pfizer-BioNTech COVID-19 Bivalent</td>
<td>59267-0565-1 59267-0565-01</td>
<td>Booster: Refer to FDA/CDC Guidance</td>
</tr>
<tr>
<td>#91308</td>
<td>#0081A (1st Dose) #0082A (2nd Dose) #0083A (3rd Dose)</td>
<td>6 months through 4 years</td>
<td>Pfizer, Inc</td>
<td>Pfizer-BioNTech COVID-19 Vaccine</td>
<td>59267-0078-1 59267-0078-01 59267-0078-4 59267-0078-04</td>
<td>1st Dose to 2nd Dose: 21 Days 2nd Dose to 3rd Dose: Refer to FDA/CDC Guidance</td>
</tr>
</tbody>
</table>
### CPT® Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

<table>
<thead>
<tr>
<th>Vaccine Code</th>
<th>Vaccine Administration Code(s)</th>
<th>Patient Age</th>
<th>Vaccine Manufacturer</th>
<th>Vaccine Name(s)</th>
<th>NDC 10/NDC 11 Labeler Product ID (Vial)</th>
<th>Dosing Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>#91317</td>
<td>#0173A (3rd Dose)</td>
<td>6 months; through 4 years</td>
<td>Pfizer, Inc</td>
<td>Pfizer-BioNTech COVID-19 Bivalent</td>
<td>59267-0609-1 59267-0609-01</td>
<td>3rd Dose: Refer to FDA/CDC Guidance</td>
</tr>
<tr>
<td>#91301</td>
<td>0011A (1st Dose) 0012A (2nd Dose) 0013A (3rd Dose)</td>
<td>1812 years and older</td>
<td>Moderna, Inc</td>
<td>Moderna COVID-19 Vaccine/spikevax</td>
<td>80777-273-10 80777-0273-10 80777-100-11 80777-0100-11</td>
<td>1st Dose to 2nd Dose: 28 Days 2nd Dose to 3rd Dose (CDC recommended population(s) [eg, immunocompromised]): 28 or More Days</td>
</tr>
<tr>
<td>#91306</td>
<td>#0064A (Booster)</td>
<td>18 years and older</td>
<td>Moderna, Inc</td>
<td>Moderna COVID-19 Vaccine</td>
<td>80777-273-10 80777-0273-10</td>
<td>Refer to FDA/CDC Guidance</td>
</tr>
<tr>
<td>#91313</td>
<td>#0134A (Booster)</td>
<td>1812 years and older</td>
<td>Moderna, Inc</td>
<td>Moderna</td>
<td>80777-282-05 80777-0282-05</td>
<td>Booster: Refer to FDA/CDC Guidance</td>
</tr>
</tbody>
</table>
## CPT® Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

<table>
<thead>
<tr>
<th>Vaccine Code</th>
<th>Vaccine Administration Code(s)</th>
<th>Patient Age</th>
<th>Vaccine Manufacturer</th>
<th>Vaccine Name(s)</th>
<th>NDC 10/NDC 11 Labeler Product ID (Vial)</th>
<th>Dosing Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>(SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use</td>
<td></td>
<td>12 years through 17 years: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</td>
<td>COVID-19 Vaccine, Bivalent</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>#91314 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use</td>
<td>#0144A (Booster)</td>
<td>6 years through 11 years</td>
<td>Moderna, Inc</td>
<td>Moderna COVID-19 Vaccine, Bivalent</td>
<td>80777-282-05 80777-0282-05 Booster: Refer to FDA/CDC Guidance</td>
<td></td>
</tr>
<tr>
<td>#91311 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use</td>
<td>#0111A (1st Dose) #0112A (2nd Dose) #0113A (3rd Dose)</td>
<td>6 months through 5 years</td>
<td>Moderna, Inc</td>
<td>Moderna COVID-19 Vaccine</td>
<td>80777-279-05 80777-0279-05 1st Dose to 2nd Dose: 1 Month 2nd Dose to 3rd Dose (CDC recommended population[s] [eg, immunocompromised]): 1 Month</td>
<td></td>
</tr>
</tbody>
</table>
# CPT® Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

<table>
<thead>
<tr>
<th>Vaccine Code</th>
<th>Vaccine Administration Code(s)</th>
<th>Patient Age</th>
<th>Vaccine Manufacturer</th>
<th>Vaccine Name(s)</th>
<th>NDC 10/NDC 11 Labeler Product ID (Vial)</th>
<th>Dosing Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>91316</td>
<td>•0164A (Booster)</td>
<td>6 months, through 5 years</td>
<td>Moderna, Inc</td>
<td>Moderna COVID-19 Vaccine, Bivalent</td>
<td>80777-283-02, 80777-0283-02</td>
<td>Booster: Refer to FDA/CDC Guidance</td>
</tr>
<tr>
<td>91309</td>
<td>•0091A (1st Dose) •0092A (2nd Dose) •0093A (3rd Dose)</td>
<td>6 years through 11 years</td>
<td>Moderna, Inc</td>
<td>Moderna COVID-19 Vaccine</td>
<td>80777-275-05, 80777-0275-05</td>
<td>1st Dose to 2nd Dose: 1 Month 2nd Dose to 3rd Dose (CDC recommended population[s] [eg, immunocompromised]): 1 Month</td>
</tr>
<tr>
<td></td>
<td>•▲0094A (Booster)</td>
<td>18 years and older</td>
<td>Moderna, Inc</td>
<td>Moderna COVID-19 Vaccine</td>
<td>80777-275-05, 80777-0275-05</td>
<td>Booster: Refer to FDA/CDC Guidance</td>
</tr>
<tr>
<td>91302</td>
<td>•0021A (1st Dose) •0022A (2nd Dose)</td>
<td>18 years and older</td>
<td>AstraZeneca, Plc</td>
<td>AstraZeneca COVID-19 Vaccine</td>
<td>0310-1222-10, 00310-1222-10</td>
<td>28 Days</td>
</tr>
</tbody>
</table>
# CPT® Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

<table>
<thead>
<tr>
<th>Vaccine Code</th>
<th>Vaccine Administration Code(s)</th>
<th>Patient Age</th>
<th>Vaccine Manufacturer</th>
<th>Vaccine Name(s)</th>
<th>NDC 10/NDC 11 Labeler Product ID (Vial)</th>
<th>Dosing Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>#91303</td>
<td>••0031A (Single Dose)</td>
<td>18 years and older</td>
<td>Janssen</td>
<td>Janssen COVID-19 Vaccine</td>
<td>59676-580-05 59676-0580-05</td>
<td>Not Applicable</td>
</tr>
<tr>
<td></td>
<td>••0034A (Booster)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Booster: Refer to FDA/CDC Guidance</td>
</tr>
<tr>
<td>#91304</td>
<td>•0041A (1st Dose)</td>
<td>18-12 years and older</td>
<td>Novavax, Inc</td>
<td>Novavax COVID-19 Vaccine</td>
<td>80631-100-01 80631-1000-01</td>
<td>21 Days</td>
</tr>
<tr>
<td></td>
<td>•0042A (2nd Dose)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Booster: Refer to FDA/CDC Guidance</td>
</tr>
<tr>
<td></td>
<td>•0044A (Booster)</td>
<td>18 years and older</td>
<td>Novavax, Inc</td>
<td>Novavax COVID-19 Vaccine</td>
<td>80631-100-01 80631-1000-01</td>
<td>BOOSTER: Refer to FDA/CDC Guidance</td>
</tr>
<tr>
<td>#91310</td>
<td>•0104A (Booster)</td>
<td>18 years and older</td>
<td>Sanofi Pasteur</td>
<td>Sanofi Pasteur COVID-19 Vaccine (Adjuvanted For Booster Immunization)</td>
<td>49281-618-20 49281-0618-20</td>
<td>Booster: Refer to FDA/CDC Guidance</td>
</tr>
</tbody>
</table>

CPT © Copyright 2022 American Medical Association. 
All rights reserved. AMA and CPT are registered trademarks of the American Medical Association. 
Updated December 9, 2022